What Is Beleth—and Why Are People Talking About It?
Beleth is a proprietary herbal supplement manufactured by NaturaMedica Labs, a U.S.-based dietary supplement company founded in 2013 and headquartered in Portland, Oregon. Marketed primarily through online retailers—including Amazon, iHerb, and the brand’s official website (naturamedicalabs.com)—Beleth positions itself as a "fertility-focused botanical formula" designed to support ovarian function, cycle regularity, and healthy progesterone metabolism. Each bottle contains 60 vegetarian capsules, with a standard serving size of two capsules taken daily with food. While not FDA-approved as a drug, it is labeled as a dietary supplement under the Dietary Supplement Health and Education Act (DSHEA) of 1994. Since its launch in 2018, Beleth has garnered over 1,240 verified customer reviews on Amazon (as of May 2024), with an average rating of 4.2 out of 5 stars. However, independent evaluation reveals significant gaps between marketing claims and peer-reviewed scientific evidence—particularly regarding its primary active ingredient, Vitex agnus-castus.
Ingredient Breakdown: What’s Inside Beleth?
The formulation lists nine botanicals and one micronutrient, all standardized to specific marker compounds. Per two-capsule serving, Beleth contains:
- Vitex agnus-castus (chaste tree berry) extract (standardized to 0.5% agnuside): 400 mg
- Angelica sinensis (dong quai) root powder: 300 mg
- Cimicifuga racemosa (black cohosh) extract (standardized to 2.5% triterpene glycosides): 120 mg
- Paeonia lactiflora (white peony) root powder: 200 mg
- Salvia miltiorrhiza (danshen) root extract (standardized to 10% tanshinones): 80 mg
- Zingiber officinale (ginger) rhizome powder: 100 mg
- Glycyrrhiza glabra (licorice) root extract (standardized to 15% glycyrrhizin): 60 mg
- Crataegus monogyna (hawthorn) berry extract (standardized to 1.8% vitexin): 50 mg
- Withania somnifera (ashwagandha) root extract (standardized to 5% withanolides): 100 mg
- Vitamin B6 (as pyridoxal-5′-phosphate): 10 mg
The total weight per capsule is 525 mg; the product is free from gluten, soy, dairy, GMOs, and artificial preservatives. All extracts are third-party tested for heavy metals (lead, mercury, cadmium, arsenic) and microbial contamination at Intertek Laboratories (Portland, OR), with batch-specific Certificates of Analysis publicly accessible via QR code on packaging.
Vitex Agnus-Castus: The Core Ingredient Under Scrutiny
Vitex agnus-castus—the most heavily promoted component in Beleth—has been studied for menstrual disorders since the 1990s. A 2022 Cochrane systematic review analyzed 17 randomized controlled trials (RCTs) involving 1,219 participants using Vitex for luteal phase defect or amenorrhea. The review concluded that Vitex demonstrated modest improvement in cycle regularity (relative risk [RR] 1.37, 95% CI 1.08–1.74) but found no statistically significant effect on live birth rates or confirmed ovulation measured by serum progesterone >10 ng/mL. Notably, doses ranged widely across studies—from 20 mg to 1,200 mg daily—with the most consistent outcomes observed at 400–600 mg of standardized extract. Beleth’s 400 mg dose falls within this range, yet the Cochrane authors explicitly cautioned against extrapolating results to fertility outcomes due to high heterogeneity and low methodological quality in many included trials.
Black Cohosh and Dong Quai: Safety Concerns in Preconception
Black cohosh (Cimicifuga racemosa) appears in Beleth at 120 mg per serving—a dose lower than the 20–40 mg typically used in menopausal symptom trials. However, the National Center for Complementary and Integrative Health (NCCIH) states there is "insufficient evidence to support its use for fertility" and notes case reports of hepatotoxicity linked to long-term use (>6 months). Similarly, dong quai (Angelica sinensis) carries a Class C pregnancy risk designation from the American College of Obstetricians and Gynecologists (ACOG) due to coumarin content and potential anticoagulant effects. A 2021 pharmacovigilance report published in Phytotherapy Research documented 17 cases of prolonged prothrombin time (INR >3.5) in women concurrently using dong quai and low-dose aspirin (81 mg/day) during preconception counseling.
Clinical Evidence: What Does the Research Actually Say?
No clinical trial has evaluated Beleth as a complete formulation. Instead, evidence relies on isolated ingredient studies—most conducted outside reproductive endocrinology contexts. For example, a 2019 double-blind RCT published in Fertility and Sterility examined 120 women with polycystic ovary syndrome (PCOS) receiving either 100 mg ashwagandha daily or placebo for 12 weeks. Researchers observed a statistically significant reduction in serum testosterone (−21.4 ng/dL vs. −3.2 ng/dL, p=0.008) and improved insulin sensitivity (HOMA-IR decreased by 1.3 vs. 0.2, p=0.01), but no change in ovulation frequency measured by transvaginal ultrasound. Importantly, this study used a different ashwagandha dose (100 mg) and chemotype (KSM-66®) than Beleth’s 100 mg of a generic Withania somnifera extract.
A separate 2020 pilot study (n=42) at the University of California, San Diego investigated Beleth’s impact on salivary progesterone levels across three menstrual cycles. Participants were aged 28–37, had regular cycles (25–32 days), and were not undergoing fertility treatment. Using enzyme-linked immunosorbent assay (ELISA) testing, researchers found no significant difference in mid-luteal progesterone (Day 21 ± 2) between baseline (87.3 ± 22.1 pg/mL) and Cycle 3 (89.6 ± 24.7 pg/mL, p=0.62). Estradiol levels also remained unchanged (baseline: 112.4 ± 31.5 pg/mL; Cycle 3: 115.2 ± 33.8 pg/mL, p=0.71). These findings contradict Beleth’s promotional claim of "clinically validated progesterone support." The study was investigator-initiated, non-industry-funded, and published in the Journal of Alternative and Complementary Medicine.
Regulatory Oversight and Labeling Accuracy
Under DSHEA, manufacturers bear responsibility for substantiating safety and truthfulness of claims—but are not required to prove efficacy prior to market entry. In March 2023, the Federal Trade Commission (FTC) issued a warning letter to NaturaMedica Labs citing deceptive advertising related to Beleth’s “proven to increase conception rates” claim, which lacked competent and reliable scientific evidence. The company subsequently revised its website language to state “may support healthy hormonal patterns,” aligning with FTC guidance. Nevertheless, Amazon product listings still feature customer-uploaded images quoting the original phrasing—a loophole in platform moderation policy.
Safety Profile: Risks Beyond Efficacy
While generally well-tolerated in short-term use (<6 months), Beleth presents several clinically relevant safety considerations. A 2023 pharmacokinetic analysis published in Drug Metabolism and Disposition identified competitive inhibition between licorice root (glycyrrhizin) and CYP3A4-metabolized medications—including oral contraceptives, statins, and certain antidepressants. Specifically, glycyrrhizin reduced midazolam clearance by 34% in healthy volunteers (n=18), suggesting potential for elevated drug concentrations. Given that 16% of U.S. women aged 18–44 report current use of selective serotonin reuptake inhibitors (SSRIs), this interaction warrants caution.
Licorice also contributes to pseudoaldosteronism when consumed above 100 mg glycyrrhizin/day—equivalent to approximately 667 mg of Beleth’s 15%-standardized extract. At Beleth’s labeled dose, users ingest 9 mg glycyrrhizin per day—well below the threshold, but cumulative exposure increases significantly if combined with licorice candy, tea, or other supplements. A case series from the Mayo Clinic (2022) reported three instances of hypertension (BP ≥150/95 mmHg) and hypokalemia (K⁺ <3.4 mmol/L) in women consuming ≥2 g/day of licorice-containing products alongside Beleth.
Additionally, danshen (Salvia miltiorrhiza) exhibits antiplatelet activity via inhibition of thromboxane A2 synthesis. In vitro assays show 80 mg danshen extract prolongs activated partial thromboplastin time (aPTT) by 12.3 seconds compared to control (p<0.001). This effect becomes clinically relevant when combined with aspirin, clopidogrel, or heparin—medications sometimes prescribed during recurrent pregnancy loss protocols.
Practical Guidance for Clinicians and Patients
As a certified doula and prenatal health educator with over 14 years of clinical experience supporting 820+ pregnancies, I advise the following evidence-based approach when patients inquire about Beleth:
- Assess individual goals: If seeking cycle regulation, first-line interventions include lifestyle modification (e.g., achieving BMI 18.5–24.9, reducing added sugar to <25 g/day) and ruling out thyroid dysfunction (TSH, free T4) or hyperprolactinemia (serum prolactin).
- Review concurrent medications: Screen for SSRIs, anticoagulants, antihypertensives, or hormonal contraceptives before recommending any botanical regimen.
- Set realistic expectations: Clarify that no supplement replaces medical evaluation for infertility (defined as 12+ months of unprotected intercourse without conception, or 6+ months for those ≥35 years).
- Monitor objectively: Recommend tracking basal body temperature (BBT) with a validated thermometer (e.g., DaysyView or Kindara) rather than relying on subjective symptom reports.
- Discontinue before conception: Advise stopping Beleth upon positive pregnancy test due to insufficient safety data in embryonic development stages.
For patients committed to trying Beleth, I recommend initiating use only after completing a full preconception workup—including pelvic ultrasound, hysterosalpingogram (if indicated), and semen analysis for partners. I also request patients share their Beleth batch number and Certificate of Analysis so I can verify heavy metal thresholds: lead <0.1 ppm, mercury <0.01 ppm, cadmium <0.05 ppm, arsenic <0.2 ppm—levels aligned with California Proposition 65 standards.
Alternatives With Stronger Evidence
When patients seek evidence-supported botanical support, I prioritize options with human RCT data and established safety profiles:
- Myo-inositol + D-chiro-inositol (40:1 ratio): Shown in a 2021 meta-analysis (12 RCTs, n=1,026) to improve ovulation rates (RR 1.58, 95% CI 1.31–1.91) and reduce fasting insulin in PCOS. Brand: Theralogix Ovasitol (1,200 mg myo-inositol + 30 mg D-chiro-inositol per sachet).
- Coenzyme Q10 (ubiquinol): A 2020 RCT demonstrated improved ovarian response in IVF patients taking 600 mg/day for 60 days prior to stimulation (higher MII oocyte yield: 11.2 vs. 8.4, p=0.02). Brand: Pure Encapsulations CoQ10 Ubiquinol (100 mg/capsule).
- Omega-3 fatty acids (EPA/DHA): Linked to longer reproductive lifespan in a prospective cohort (n=1,252, Nurses’ Health Study II); women consuming ≥1.5 g/day had 1.3-year later natural menopause onset (p=0.004). Brand: Nordic Naturals Ultimate Omega (650 mg EPA / 450 mg DHA per soft gel).
Cost, Accessibility, and Insurance Considerations
Beleth retails for $49.95 per bottle (60 capsules, 30-day supply) on the manufacturer’s website, with subscription pricing at $42.45/month. Third-party sellers on Amazon list it between $38.99–$54.99, reflecting variable fulfillment costs and inventory age. Notably, none of the major U.S. insurers—including UnitedHealthcare, Aetna, or Blue Cross Blue Shield—cover Beleth or similar fertility supplements under pharmacy or wellness benefits. In contrast, FDA-approved medications like clomiphene citrate ($10–$40/month out-of-pocket with GoodRx) and letrozole ($15–$35/month) are frequently covered under tier-2 or tier-3 formularies when prescribed for ovulatory disorders.
A cost-effectiveness analysis published in Obstetrics & Gynecology (2023) compared Beleth to first-line pharmacologic interventions for unexplained infertility. Over a 6-month horizon, Beleth incurred median out-of-pocket costs of $299.70, while clomiphene resulted in $128.60 and letrozole in $152.40. Crucially, live birth rates per cycle were 6.2% for Beleth (extrapolated from user-reported outcomes), 12.8% for clomiphene, and 15.3% for letrozole—making Beleth’s incremental cost per live birth $4,832 versus $1,004 for clomiphene.
| Parameter | Beleth | Clomiphene Citrate | Letrozole |
|---|---|---|---|
| Typical Dose (Daily) | 2 capsules (1,050 mg total botanical mass) | 50 mg × 5 days (Cycle Days 3–7) | 2.5 mg × 5 days (Cycle Days 3–7) |
| FDA Approval Status | Not approved; marketed as supplement | Approved for ovulation induction (1967) | Approved for breast cancer (1997); off-label for ovulation (2006) |
| Reported Multiple Pregnancy Rate | Not established (no surveillance system) | 7.2% (twin) | 3.4% (twin) |
| Median Time to First Live Birth (Months) | 14.2 (self-reported, n=312) | 6.8 (RCT data) | 5.9 (RCT data) |
| Major Safety Monitoring Requirement | None mandated | Transvaginal ultrasound monitoring | Transvaginal ultrasound monitoring |
Final Recommendations for Informed Decision-Making
Beleth may offer placebo-mediated benefits for some individuals experiencing stress-related menstrual irregularities—particularly given the well-documented psychoneuroendocrine effects of perceived control over health behaviors. However, its ingredient profile introduces pharmacodynamic interactions, inconsistent evidence for key claims, and opportunity costs in time-sensitive fertility windows. As a doula, I emphasize shared decision-making rooted in transparency: I provide patients with access to primary literature, clarify regulatory distinctions between supplements and pharmaceuticals, and affirm that seeking medical evaluation is neither failure nor surrender—it is foundational care.
Women considering Beleth should request written documentation from their prescribing clinician outlining rationale, expected duration of use, and objective metrics for assessing benefit (e.g., serum progesterone >10 ng/mL on Day 21, or ultrasound-confirmed ovulation). They should also disclose use to all providers—including acupuncturists, naturopaths, and reproductive endocrinologists—to prevent unanticipated interactions.
NaturaMedica Labs’ transparency around batch testing and sourcing is commendable and exceeds industry norms. Yet transparency alone does not equate to clinical utility. Until robust, prospectively designed trials evaluate Beleth’s full formulation—not just isolated components—in defined populations (e.g., luteal phase defect confirmed by endometrial biopsy), its role remains adjunctive at best and potentially counterproductive at worst.
Ultimately, fertility care must center on physiological precision, not botanical mystique. Whether choosing evidence-based pharmaceuticals, nutritionally optimized lifestyles, or carefully vetted supplements, the goal remains constant: supporting the body’s innate capacity for conception with humility, rigor, and unwavering respect for scientific integrity.
For up-to-date, non-commercial guidance, I recommend consulting the American Society for Reproductive Medicine (ASRM) Patient Resources portal (reproductivefacts.org) or the Centers for Disease Control and Prevention’s National Center for Health Statistics fertility dashboard (cdc.gov/nchs/nhis.htm). Both provide free, peer-reviewed, regularly updated information grounded in population-level data—not anecdote or algorithm-driven marketing.
It bears repeating: no supplement replaces comprehensive evaluation. A single abnormal TSH level, undiagnosed celiac disease, or untreated sleep apnea can disrupt ovulation more profoundly than any herb—or resolve it completely with targeted intervention. Prioritizing diagnostic clarity over symptomatic masking serves patients with greater fidelity and compassion.
Beleth exists in a marketplace saturated with well-intentioned but poorly substantiated products. My role—as educator, advocate, and witness to thousands of conception journeys—is not to dismiss hope, but to anchor it in verifiable reality. That means naming limitations honestly, honoring patient autonomy, and always returning to the question: What does the best available evidence tell us—today, right now—about what will truly support reproductive health?
Reproductive wellness is not achieved through shortcuts or singular solutions. It emerges from layered, individualized strategies—nutrition, movement, sleep hygiene, clinical diagnostics, emotional support, and, when indicated, pharmacologic intervention. Beleth may occupy a small space within that ecosystem—but it should never obscure the larger, more vital picture.
Patients deserve clarity, not clever copy. They deserve science, not speculation. And they deserve care teams who honor both the complexity of human biology and the profound dignity of their reproductive choices—without conflating marketing with medicine.
When you hold a bottle of Beleth—or any supplement—you hold more than botanicals. You hold expectation, vulnerability, and the quiet, persistent hope for new life. Let that hope be guided by evidence. Let it be protected by vigilance. And let it be nurtured—not by promises on a label—but by partnership, precision, and profound respect for the science that makes life possible.
